Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corbus Pharmaceuticals ( (CRBP) ) has shared an announcement.
On October 18, 2025, Corbus Pharmaceuticals announced data from its Phase 1/2 clinical study of CRB-701, presented at the 2025 European Society for Medical Oncology Congress. The study, involving 167 patients with various tumor types, demonstrated promising efficacy and a favorable safety profile, with no dose-limiting toxicities and low discontinuation rates. The results suggest potential differentiation from other experimental agents in head and neck squamous cell carcinoma (HNSCC) and cervical cancers, highlighting a significant unmet need in these areas. Corbus plans to initiate registrational studies by mid-2026, aiming to further develop CRB-701 as a treatment option for patients with advanced solid tumors.
The most recent analyst rating on (CRBP) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio, focusing on innovative scientific approaches to well-understood biological pathways. The company’s pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 inverse agonist for obesity treatment. Corbus is headquartered in Norwood, Massachusetts.
Average Trading Volume: 160,275
Technical Sentiment Signal: Buy
Current Market Cap: $236.8M
Find detailed analytics on CRBP stock on TipRanks’ Stock Analysis page.